The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.

OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and ...

Maybe I'm an arrogant Luddite, but I still think I can write a better column about Indiana than artificial intelligence can.

Patel, Trump’s nominee to be FBI director, was paid $25,000 last year by a film company that has promoted anti-Western views ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

We expect Lilly to continue to grow faster than the market, and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Lilly's fourth-quarter profit doubles, driven by diabetes and obesity treatments. Strong revenue and forecast for 2025.